Leukodystrophies are genetic disorders that affect development or maintenance of the white matter of the central nervous system (CNS).^[@bibr1-2329048X20939003][@bibr2-2329048X20939003]-[@bibr3-2329048X20939003]^ Leukodystrophies have an incidence of almost 1 in 7500 live births, with significant morbidities and death in a third by age 8.^[@bibr4-2329048X20939003]^ A confounding feature to understanding leukodystrophies is their apparent genetic and mechanistic heterogeneity.^[@bibr5-2329048X20939003]^ Further, even with advanced next-generation sequencing (NGS) approaches, diagnosis rates remain below 70%,^[@bibr6-2329048X20939003]^ suggesting that a quarter of disease-causing genes may not even be known.

A variety of approaches to define and categorize leukodystrophies have been pursued. An international committee of experts classified 30 disorders as leukodystrophies.^[@bibr7-2329048X20939003]^ They defined leukodystrophies as genetic, with T2 signal abnormality on magnetic resonance imaging (MRI), and including glial or myelin sheath abnormalities in the CNS. Further, they termed "genetic leukoencephalopathies" to describe disorders that are heritable and result in white matter abnormalities but that did not necessarily meet their strict criteria as a leukodystrophy. Also, more recent classification schemes have been proposed for leukodystrophies, for example, recognizing the complex pathology of different cell types^[@bibr5-2329048X20939003]^ or emphasizing the sorting of leukodystrophies into different types based on disease pathology such as hypomyelination or vasculature involvement.^[@bibr8-2329048X20939003]^

Our objective was to identify and include all genes that have been reported to cause T2 white matter abnormalities. Our hypothesis was that a more complete list of genes associated with leukodystrophies and leukoencephalopathies, which we will term "genetic white matter disorders (GWMD)," would be of utility for improving diagnostic yield in genetic testing, and would reveal unexpected shared mechanistic pathways. We chose not to exclude any apparent genetic cause, even if not historically considered as a leukodystrophy or leukoencephalopathy. A secondary aim was to determine whether there were any common genetic or mechanistic pathways identified by grouping similar disorders.

Methods {#section1-2329048X20939003}
=======

We conducted a systematic search using keywords "leukodystrophy" or "leukoencephalopathy," including of PubMed, Google, published literature reviews, and commercial gene panels ([Figure 1](#fig1-2329048X20939003){ref-type="fig"}). We included for consideration any publication reporting white matter signal changes on MRI in human patients. The timeline for publication was January 1, 1990, through December 31, 2018. Inclusion required a published report of abnormal T2 white matter signal abnormality on brain MRI. Exclusion criteria included any white matter change secondary to nongenetic cause, including traumatic, infectious, or autoimmune etiologies. We excluded any genomic-level structural chromosomal changes (deletion, duplication); we also excluded gray matter pathology without white matter involvement, brain iron disorders, and isolated atrophy, thinning, reduced volume, or absence of structures (eg, absence of the corpus callosum). Following review and manual curation, genes were characterized and grouped. We categorized genes as being hypomyelinating if they were specifically stated as such in published literature. We used the same criteria to identify genes reported to cause contrast enhancement. Each gene was linked with its Ensembl stable gene ID from Ensembl 92.^[@bibr9-2329048X20939003]^

![Schematic diagram of gene identification.](10.1177_2329048X20939003-fig1){#fig1-2329048X20939003}

Seven hundred fifty-one disorders of white matter were identified, including from publications^[@bibr7-2329048X20939003],[@bibr10-2329048X20939003][@bibr11-2329048X20939003][@bibr12-2329048X20939003][@bibr13-2329048X20939003][@bibr14-2329048X20939003][@bibr15-2329048X20939003][@bibr16-2329048X20939003]-[@bibr17-2329048X20939003]^; lists from gene panel testing from GeneDx (<https://www.genedx.com/test-catalog/available-tests/leukodystrophy-xpanded-panel/>), the United Kingdom National Health Service (<https://ukgtn.nhs.uk/find-a-test/search-by-disorder-gene/leukodystrophy-hypomyelinating-and-mitochondrial-leukoencephalopathy-96>-gene-panel-899/), the scientific crowdsourcing resource Genomics England PanelApp version 1.60 (<https://panelapp.genomicsengland.co.uk/panels/42>/), Invitae (<https://www.invitae.com/en/physician/tests/06155>/), and the University of Chicago (<https://dnatesting.uchicago.edu/sites/default/files/media/documents/Rett> Angelman Information Sheet 4-27-17.pdf). The 751 disorders were limited to 728 genetic diseases, and then to 613 unique genes. Each gene was then reviewed in Online Mendelian Inheritance of Man, and if necessary searches were performed in PubMed to determine whether published examples of T2 MRI white matter changes were reported. Disorders involving nongenetic causes (eg, HIV, cytomegalovirus, dietary B12 deficiency) and portions of chromosomes (eg, 18q Deletion Syndrome, etc) were excluded. Disorders affecting only peripheral myelin were excluded.

Ensembl gene IDs were used to analyze the data on 2 platforms. To categorize the genes by biologic process and metabolic process, we used the Gene Ontology (GO) PANTHER classification system (PANTHER14.1).^[@bibr18-2329048X20939003][@bibr19-2329048X20939003]-[@bibr20-2329048X20939003]^ To conduct pathway analysis, we used Reactome, a biological pathway and process analysis database and visualization tool.^[@bibr21-2329048X20939003]^ Seventy-six leukodystrophy genes could not be mapped to a gene or process in Reactome.

Results {#section2-2329048X20939003}
=======

Using a comprehensive review of PubMed, Google, published literature reviews, and commercial gene panels, we identified 399 unique genes with white matter MRI pathology on T2 sequences ([Figure 1](#fig1-2329048X20939003){ref-type="fig"}; [Table 1](#table1-2329048X20939003){ref-type="table"}). Of this, 87 (22%) genes were hypomyelinating. Only 3 genes had contrast enhancement on MRI (*ABCD1*, *GFAP*, and *UNC13D*) ([Table 2](#table2-2329048X20939003){ref-type="table"}).

###### 

List of All Identified Genetic White Matter Disorders (GWMD) Genes.
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  Gene name       Ensembl ID
  --------------- -----------------
  AARS            ENSG00000090861
  AARS2           ENSG00000124608
  ABAT            ENSG00000183044
  ABCA1           ENSG00000165029
  ABCD1           ENSG00000101986
  ACDB5           ENSG00000107897
  ACER3           ENSG00000078124
  ACOX1           ENSG00000161533
  ACP33           ENSG00000090487
  ACP5            ENSG00000102575
  ACSF3           ENSG00000176715
  ADAR            ENSG00000160710
  ADGRG1          ENSG00000205336
  ADSL            ENSG00000239900
  AGA             ENSG00000038002
  AHDC1           ENSG00000126705
  AIMP1           ENSG00000164022
  AIMP2           ENSG00000106305
  ALDH3A2         ENSG00000072210
  ALDH5A1         ENSG00000112294
  ALDH6A1         ENSG00000119711
  ALDH7A1         ENSG00000164904
  ALG12           ENSG00000182858
  ALG13           ENSG00000101901
  ALG2            ENSG00000119523
  ALG6            ENSG00000088035
  ALG9            ENSG00000086848
  AMACR           ENSG00000242110
  AMPD2           ENSG00000116337
  AP4B1           ENSG00000134262
  AP5Z1           ENSG00000242802
  APOPT1          ENSG00000256053
  APP             ENSG00000142192
  ARHGAP31        ENSG00000031081
  ARHGEF10        ENSG00000104728
  ARNT2           ENSG00000172379
  ARSA            ENSG00000100299
  ASL             ENSG00000126522
  ASNS            ENSG00000070669
  ASPA            ENSG00000108381
  ASS1            ENSG00000130707
  ASXL1           ENSG00000171456
  ATN1            ENSG00000111676
  ATP7B           ENSG00000123191
  ATPAF2          ENSG00000171953
  ATRX            ENSG00000085224
  AUH             ENSG00000148090
  B3GALNT2        ENSG00000162885
  BCAP31          ENSG00000185825
  BCKDHA          ENSG00000248098
  BCKDHB          ENSG00000083123
  BCS1L           ENSG00000074582
  BOLA3           ENSG00000163170
  BRAT1           ENSG00000106009
  BTD             ENSG00000169814
  CARS2           ENSG00000134905
  CDKL5           ENSG00000008086
  CLCN2           ENSG00000114859
  CLN8            ENSG00000182372
  CLP1            ENSG00000172409
  CLPP            ENSG00000125656
  CNTNAP1         ENSG00000108797
  COA7            ENSG00000162377
  COG7            ENSG00000168434
  COL4A1          ENSG00000187498
  COQ2            ENSG00000173085
  COQ8A           ENSG00000163050
  COQ9            ENSG00000088682
  COX10           ENSG00000006695
  COX14           ENSG00000178449
  COX15           ENSG00000014919
  COX6B1          ENSG00000126267
  COX7B           ENSG00000131174
  COX8A           ENSG00000176340
  CSF1R           ENSG00000182578
  CTC1            ENSG00000178971
  CTDP1           ENSG00000282752
  CTSA            ENSG00000064601
  CTSD            ENSG00000117984
  CTSF            ENSG00000174080
  CYP27A1         ENSG00000135929
  CYP2U1          ENSG00000155016
  CYP7B1          ENSG00000172817
  D2HGDH          ENSG00000180902
  DAG1            ENSG00000173402
  DARS            ENSG00000115866
  DARS2           ENSG00000117593
  DBT             ENSG00000137992
  DCAF17          ENSG00000115827
  DCX             ENSG00000077279
  DDC             ENSG00000132437
  DDHD2           ENSG00000085788
  DEAF1           ENSG00000177030
  DGUOK           ENSG00000114956
  DHFR            ENSG00000228716
  DLD             ENSG00000091140
  DMPK            ENSG00000104936
  DNM1L           ENSG00000087470
  DOCK6           ENSG00000130158
  DOLK            ENSG00000175283
  DPAGT1          ENSG00000172269
  DPM1            ENSG00000000419
  DPYD            ENSG00000188641
  EARS2           ENSG00000103356
  EHMT1           ENSG00000181090
  EIF2B1          ENSG00000111361
  EIF2B2          ENSG00000119718
  EIF2B3          ENSG00000070785
  EIF2B4          ENSG00000115211
  EIF2B5          ENSG00000145191
  ELOVL4          ENSG00000118402
  EPG5            ENSG00000152223
  EPRS            ENSG00000136628
  ERCC2           ENSG00000104884
  ERCC3           ENSG00000163161
  ERCC6           ENSG00000225830
  ERCC8           ENSG00000049167
  ETFDH           ENSG00000171503
  ETHE1           ENSG00000105755
  FA2H            ENSG00000103089
  FAM126A         ENSG00000122591
  FARS2           ENSG00000145982
  FASTKD2         ENSG00000118246
  FBXL4           ENSG00000112234
  FH              ENSG00000091483
  FIG4            ENSG00000112367
  FKRP            ENSG00000181027
  FKTN            ENSG00000106692
  FMR1            ENSG00000102081
  FOLR1           ENSG00000110195
  FOXC1           ENSG00000054598
  FOXRED1         ENSG00000110074
  FUCA1           ENSG00000179163
  GAA             ENSG00000171298
  GALC            ENSG00000054983
  GALT            ENSG00000213930
  GAN             ENSG00000261609
  GBA             ENSG00000177628
  GBE1            ENSG00000114480
  GCDH            ENSG00000105607
  GFAP            ENSG00000131095
  GFM1            ENSG00000168827
  GJA1            ENSG00000152661
  GJB1            ENSG00000169562
  GJC2            ENSG00000198835
  GLA             ENSG00000102393
  GLB1            ENSG00000170266
  GLRX5           ENSG00000182512
  GLUL            ENSG00000135821
  GLYCTK          ENSG00000168237
  GM2A            ENSG00000196743
  GNAO1           ENSG00000087258
  GNS             ENSG00000135677
  GPHN            ENSG00000171723
  HEPACAM         ENSG00000165478
  HEXA            ENSG00000213614
  HHH/ SLC25A15   ENSG00000102743
  HIBCH           ENSG00000198130
  HIKESHI         ENSG00000149196
  HLCS            ENSG00000159267
  HMBS            ENSG00000256269
  HMGCL           ENSG00000117305
  HSD17B10        ENSG00000072506
  HSD17B4         ENSG00000133835
  HSPD1           ENSG00000144381
  HTRA1           ENSG00000166033
  IBA57           ENSG00000181873
  IDS             ENSG00000010404
  IDUA            ENSG00000127415
  IFIH1           ENSG00000115267
  ISCA1           ENSG00000135070
  ISCA2           ENSG00000165898
  ITPA            ENSG00000125877
  IVD             ENSG00000128928
  JAM3            ENSG00000166086
  KCNT1           ENSG00000107147
  L2HGDH          ENSG00000087299
  LAMA1           ENSG00000101680
  LAMA2           ENSG00000196569
  LAMB1           ENSG00000091136
  LARGE1          ENSG00000133424
  LETM1           ENSG00000168924
  LIAS            ENSG00000121897
  LIPT1           ENSG00000144182
  LMNB1           ENSG00000113368
  LRPPRC          ENSG00000138095
  LYRM7           ENSG00000186687
  MAG             ENSG00000105695
  MAN2B1          ENSG00000104774
  MANBA           ENSG00000109323
  MARS2           ENSG00000247626
  MAT1A           ENSG00000151224
  MCCC1           ENSG00000078070
  MCOLN1          ENSG00000090674
  MECP2           ENSG00000169057
  MEF2C           ENSG00000081189
  MFSD8           ENSG00000164073
  MGP             ENSG00000111341
  MLC1            ENSG00000100427
  MLYCD           ENSG00000103150
  MMACHC          ENSG00000132763
  MMADHC          ENSG00000168288
  MOCS1           ENSG00000124615
  MOCS2           ENSG00000164172
  MOGS            ENSG00000115275
  MPLKIP          ENSG00000168303
  MPV17           ENSG00000115204
  MRPS16          ENSG00000182180
  MRPS22          ENSG00000175110
  MTATP6          ENSG00000198899
  MTFMT           ENSG00000103707
  MTHFR           ENSG00000177000
  MTHFS           ENSG00000136371
  MTND1           ENSG00000198888
  MTND5           ENSG00000198786
  MTND6           ENSG00000198695
  MTTC            ENSG00000210140
  MTTF            ENSG00000210049
  MTTH            ENSG00000210176
  MTTK            ENSG00000210156
  MTTL1           ENSG00000209082
  MTTQ            ENSG00000210107
  MTTS1           ENSG00000210151
  MTTS2           ENSG00000210184
  NADK2           ENSG00000152620
  NAGLU           ENSG00000108784
  NAGS            ENSG00000161653
  NAXE            ENSG00000163382
  NDUFA10         ENSG00000130414
  NDUFA12         ENSG00000184752
  NDUFA2          ENSG00000131495
  NDUFA9          ENSG00000139180
  NDUFAF1         ENSG00000137806
  NDUFAF2         ENSG00000164182
  NDUFAF3         ENSG00000178057
  NDUFAF4         ENSG00000123545
  NDUFAF5         ENSG00000101247
  NDUFAF6         ENSG00000156170
  NDUFB3          ENSG00000119013
  NDUFB9          ENSG00000147684
  NDUFS1          ENSG00000023228
  NDUFS2          ENSG00000158864
  NDUFS3          ENSG00000213619
  NDUFS4          ENSG00000164258
  NDUFS6          ENSG00000145494
  NDUFS7          ENSG00000115286
  NDUFS8          ENSG00000110717
  NDUFV1          ENSG00000167792
  NDUFV2          ENSG00000178127
  NFU1            ENSG00000169599
  NGLY1           ENSG00000151092
  NKX6-2          ENSG00000148826
  NOTCH1          ENSG00000148400
  NOTCH3          ENSG00000074181
  NPC1            ENSG00000141458
  NPC2            ENSG00000119655
  NUBPL           ENSG00000151413
  OAT             ENSG00000065154
  OCLN            ENSG00000197822
  OCRL            ENSG00000122126
  OPA1            ENSG00000198836
  OPA3            ENSG00000125741
  OSGEP           ENSG00000092094
  OSTM1           ENSG00000081087
  OTC             ENSG00000036473
  PAFAH1B1        ENSG00000007168
  PAH             ENSG00000171759
  PC              ENSG00000173599
  PCCA            ENSG00000175198
  PCCB            ENSG00000114054
  PDHA1           ENSG00000131828
  PDHX            ENSG00000110435
  PEX1            ENSG00000127980
  PEX10           ENSG00000157911
  PEX12           ENSG00000108733
  PEX13           ENSG00000162928
  PEX14           ENSG00000142655
  PEX16           ENSG00000121680
  PEX19           ENSG00000162735
  PEX26           ENSG00000215193
  PEX5            ENSG00000139197
  PEX6            ENSG00000124587
  PGAP1           ENSG00000197121
  PGN             ENSG00000197912
  PHGDH           ENSG00000092621
  PHYH            ENSG00000107537
  PIGA            ENSG00000165195
  PLA2G6          ENSG00000184381
  PLEKHG2         ENSG00000090924
  PLP1            ENSG00000123560
  PMM2            ENSG00000140650
  PMP22           ENSG00000109099
  POLG1           ENSG00000140521
  POLG2           ENSG00000256525
  POLR1A          ENSG00000068654
  POLR1C          ENSG00000171453
  POLR3A          ENSG00000148606
  POLR3B          ENSG00000013503
  POMGNT1         ENSG00000085998
  POMK            ENSG00000185900
  POMT1           ENSG00000130714
  POMT2           ENSG00000009830
  PPP1R15B        ENSG00000158615
  PPT1            ENSG00000131238
  PRF1            ENSG00000180644
  PRKDC           ENSG00000253729
  PRODH           ENSG00000100033
  PRUNE1          ENSG00000143363
  PSAP            ENSG00000197746
  PSAT1           ENSG00000135069
  PSEN1           ENSG00000080815
  PURA            ENSG00000185129
  PYCR2           ENSG00000143811
  QARS            ENSG00000172053
  RAB11B          ENSG00000185236
  RARS            ENSG00000113643
  RARS2           ENSG00000146282
  RMND1           ENSG00000155906
  RNASEH2A        ENSG00000104889
  RNASEH2B        ENSG00000136104
  RNASEH2C        ENSG00000172922
  RNASET2         ENSG00000026297
  RNF216          ENSG00000011275
  RPIA            ENSG00000153574
  RPS6KC1         ENSG00000136643
  RRM2B           ENSG00000048392
  RXYLT1          ENSG00000118600
  SAMHD1          ENSG00000101347
  SCO2            ENSG00000130489
  SCP2            ENSG00000116171
  SDHA            ENSG00000073578
  SDHAF1          ENSG00000205138
  SDHB            ENSG00000117118
  SDHD            ENSG00000204370
  SEPSECS         ENSG00000109618
  SGSH            ENSG00000181523
  SHPK            ENSG00000197417
  SLC13A5         ENSG00000141485
  SLC16A2         ENSG00000147100
  SLC17A5         ENSG00000119899
  SLC1A4          ENSG00000115902
  SLC25A1         ENSG00000100075
  SLC25A12        ENSG00000115840
  SLC25A22        ENSG00000177542
  SLC33A1         ENSG00000169359
  SLC35A2         ENSG00000102100
  SLC46A1         ENSG00000076351
  SNIP1           ENSG00000163877
  SNORD118        ENSG00000200463
  SOD1            ENSG00000142168
  SOX10           ENSG00000100146
  SP110           ENSG00000135899
  SPATA5          ENSG00000145375
  SPG11           ENSG00000104133
  SPG20           ENSG00000133104
  SPTAN1          ENSG00000197694
  SRD5A3          ENSG00000128039
  STAMBP          ENSG00000124356
  STN1            ENSG00000107960
  STXBP1          ENSG00000136854
  STXBP2          ENSG00000076944
  SUCLA2          ENSG00000136143
  SUMF1           ENSG00000144455
  SUOX            ENSG00000139531
  SURF1           ENSG00000148290
  TACO1           ENSG00000136463
  TAF2            ENSG00000064313
  TBX1            ENSG00000184058
  TCF4            ENSG00000196628
  TCIRG1          ENSG00000110719
  TM4SF20         ENSG00000168955
  TMEM106B        ENSG00000106460
  TMEM165         ENSG00000134851
  TMEM70          ENSG00000175606
  TMTC3           ENSG00000139324
  TRAPPC9         ENSG00000167632
  TREM2           ENSG00000095970
  TREX1           ENSG00000213689
  TRMT5           ENSG00000126814
  TSC1            ENSG00000165699
  TSEN54          ENSG00000182173
  TUBB4A          ENSG00000104833
  TUFM            ENSG00000178952
  TWNK            ENSG00000107815
  TYMP            ENSG00000025708
  TYROBP          ENSG00000011600
  UBE2A           ENSG00000077721
  UBE3A           ENSG00000114062
  UFM1            ENSG00000120686
  UGT1A1          ENSG00000241635
  UNC13D          ENSG00000092929
  UPB1            ENSG00000100024
  VARS2           ENSG00000137411
  VPS11           ENSG00000160695
  WT1             ENSG00000184937
  WWOX            ENSG00000186153
  ZFYVE26         ENSG00000072121
  ZNF335          ENSG00000198026
  ZNF9            ENSG00000169714

###### 

List of Genes With Hypomyelination, List of Genes With Contrast Enhancement.

![](10.1177_2329048X20939003-table2)

  ---------------------- ----------
  Hypomyelinating        
  AARS                   PRKDC
  AIMP2                  PRUNE1
  ALG2                   PURA
  B3GALNT2               PYCR2
  BCAP31                 QARS
  CLCN2                  RARS
  CNTNAP1                RMND1
  DARS                   RRM2B
  DDC                    SGSH
  DPYD                   SLC16A2
  EPRS                   SLC17A5
  ERCC2                  SLC1A4
  ERCC3                  SLC25A1
  ERCC6                  SLC25A12
  ERCC8                  SLC33A1
  FAM126A                SNIP1
  FOLR1                  SOX10
  FUCA1                  SPATA5
  GJA1                   SPG11
  GJC2                   SPTAN1
  GLB1                   STAMBP
  GLUL                   STXBP1
  HIKESHI                TMEM106B
  HSPD1                  TMTC3
  MMADHC                 TSC1
  MPLKIP                 TUBB4A
  MTHFS                  UFM1
  NKX6-2                 VSP11
  NPC1                   WT1
  NPC2                   ZNF335
  OSTM1                  
  PAH                    
  PLP1                   
  POLR1C                 
  POLR3A                 
  POLR3B                 
  POMK                   
  Contrast enhancement   
  ABCD1                  
  GFAP                   
  UNC13D                 
  ---------------------- ----------

Gene Ontology term evaluation showed that the most frequent categories of GWMD genes ([Figure 2A](#fig2-2329048X20939003){ref-type="fig"}) were metabolic processes (n = 161), cellular processes (n = 120), localization (n = 49), biological regulation (n = 34), and response to stimulus (n = 14; Supplemental Table 1). Interestingly, although the overall number of genes was fewer, the distribution and type of GO biological processes was very similar to the canonical leukodystrophy genes ([Figure 2B](#fig2-2329048X20939003){ref-type="fig"}; Supplemental Table 2).

![A, Revised genetic white matter disorders (GWMD) genes organized by Gene Ontology (GO) term biological process. B, Thirty canonical leukodystrophy genes organized by GO term biological process. C, Revised GWMD genes in the category "Metabolism" displayed by subtypes of metabolic processes.](10.1177_2329048X20939003-fig2){#fig2-2329048X20939003}

A subgroup analysis of the single largest GO term of GWMD genes, "metabolic process," showed that the most frequent GO terms in this group were organic substance metabolic process (n = 119), cellular metabolic process (n = 63), primary metabolic process (n = 20), oxidation reduction process (n = 19), and catabolic process (n = 19; [Figure 2C](#fig2-2329048X20939003){ref-type="fig"}; Supplemental Table 3).

We used a biological pathway analysis tool, Reactome,^[@bibr21-2329048X20939003]^ to identify whether GWMD genes were more represented in certain processes or shared common biological features ([Table 3](#table3-2329048X20939003){ref-type="table"}). An analysis of the 25 most significantly represented biological pathways revealed that the majority of GWMD genes were involved in just 2 general categories: metabolism (metabolism, diseases of metabolism, metabolism of amino acids, biotin metabolism, defects in vitamin and cofactor metabolism, metabolism of water soluble vitamins and cofactors, biotin transport) and respiratory electron transport/mitochondrial function (respiratory electron transport; respiratory electron transport, ATP synthesis, and heat production; citric acid cycle; complex I biogenesis) ([Figure 3](#fig3-2329048X20939003){ref-type="fig"}).

###### 

Reactome Pathway Listing of the 25 Most Overrepresented Biological Pathways, Grouped by Biological Mechanisms, and From Most to Fewest Number of Genes.^a^
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                                                                    Genes      Reactions              
  ----------------------------------------------------------------- ---------- ----------- ---------- ----------
  Metabolism                                                                                          
   Metabolism                                                       177/5569   2.18e-9     2.33e-7    250/2213
   Metabolism of amino acids and derivatives                        41/931     1.54e-5     0.001      41/283
   Diseases of metabolism                                           23/303     3.04e-7     2.31e-5    33/114
   Metabolism of water-soluble vitamins and cofactors               20/377     2.56e-4     0.009      27/140
   Defects in vitamin and cofactor metabolism                       8/70       1.67e-4     0.008      9/22
   Defects in biotin metabolism                                     6/34       1.11e-4     0.006      6/6
   Biotin transport and metabolism                                  6/48       6.85e-4     0.023      9/13
   Multiple carboxylase deficiency                                  5/32       7.18e-4     0.023      4/4
  Mitochondrial                                                                                       
   Citric acid cycle and respiratory electron transport             45/404     1.11e-16    2.79e-14   30/65
   Respiratory electron transport, ATP synthesis, heat production   38/273     1.11e-16    2.79e-14   20/29
   Respiratory electron transport                                   37/215     1.11e-16    2.79e-14   17/19
   Complex I biogenesis                                             25/144     3.66e-15    6.89e-13   13/13
  Protein                                                                                             
   Protein localization                                             29/244     2.87e-13    4.30e-11   45/53
   tRNA aminoacylation                                              15/232     1.99e-4     0.008      19/42
   Recycling of eIF2:GDP                                            5/36       0.001       0.036      2/2
  Peroxisomal                                                                                         
   Peroxisomal protein import                                       17/114     9.31e-10    1.16e-7    23/26
   Class I peroxisomal protein import                               9/40       3.08e-7     2.31e-5    6/6
  Glycosylation                                                                                       
   Diseases of glycosylation                                        22/234     1.48e-8     1.39e-6    24/77
   Diseases associated with glycosylation precursor biosynthesis    7/65       5.99e-4     0.021      8/16
   Diseases associated with *N*-glycosylation of proteins           7/49       1.11e-4     0.006      8/23
   Defective POMT1                                                  3/5        1.90e-4     0.008      1/1
   Defective POMT2                                                  3/5        1.90e-4     0.008      1/1
  Other                                                                                               
   Branched chain amino acid catabolism                             10/106     1.26e-4     0.007      11/28
   Mucopolysaccharidoses                                            6/37       1.75e-4     0.008      12/22
   Loss of MECP2 binding to DNA                                     2/2        8.98e-4     0.028      1/1

Abbreviation: FDR, false discovery rate.

^a^ Many genes are counted in more than one category (eg, metabolism, diseases of metabolism).

![Reactome pathway analysis of genetic white matter disorders (GWMD) genes. Analysis is arranged in a hierarchy, with the center of each circular "burst" as the root of one top-level pathway. Each step away from center represents the next level lower in the pathway hierarchy. Yellow-coded pathways are significantly overrepresented; light gray signifies pathways not significantly overrepresented. A, Reactome pathway analysis of entire revised GWMD gene set. B, Reactome pathway analysis of 30 canonical leukodystrophy genes. C, Reactome pathway analysis of contrast-enhancing genes. D, Reactome pathway analysis of hypomyelinating gene set.](10.1177_2329048X20939003-fig3){#fig3-2329048X20939003}

We also manually evaluated the biological roles of GWMD genes, to confirm the GO and Reactome classifications, as well as to evaluate in greater details gene functions. Genes with roles in the mitochondria or mitochondrial function (*COX7*, *HSPD1*, *RMND1*, etc) were the single largest group. Interestingly, although as expected genes with lysosomal or peroxisomal roles were frequent, GWMD genes that are transcription factors were approximately as frequent (*MEF2C*, *SOX10*, *TAF2*, etc).

Discussion {#section3-2329048X20939003}
==========

We have identified a significantly greater number of genes than previously recognized, 399, that are associated with myelin signal changes on T2 MRI. This larger group of GWMD (leukodystrophy and leukoencephalopathy) genes was similar in GO group composition to previous more restrictive definitions of leukodystrophy genes.^[@bibr7-2329048X20939003]^

Of a total of 27 possible biological pathways represented in the analysis tool Reactome, GWMD genes were present in 23 of those groups, confirming the diverse potential etiologies of GWMDs. Genes involved in metabolic pathways were the most represented group of genes.

While nearly 400 genes is a significantly larger number of genes associated with GWMDs than previously considered, it is only a small proportion (1.9%) of the estimated 21 000 protein-coding genes in the entire human genome. From this perspective, given the complexities of myelin development and maintenance, and the diverse cell types that can affect myelin involved including oligodendrocytes, astrocytes, neurons, and microglia, 399 genes seem proportionate.

The definition of leukodystrophies has been a contentious and at times divisive topic. An initial organized attempt was made in 2015,^[@bibr7-2329048X20939003]^ but already in a short period of time new data suggested potential revisions to this list of approximately 30 genes.^[@bibr8-2329048X20939003]^

Our approach consisted solely of inclusion based on the presence of white matter T2 signal hyperintensity on MRI and presumed/proven genetic etiology. This methodology poses certain limitations, in that there is no consistent pathophysiology. However, this limitation is also a strength in avoiding certain biases. Since T2 signal hyperintensity of the myelin is essentially a defining term of glial/myelin sheath abnormality,^[@bibr22-2329048X20939003]^ this meets the Vanderver et al^[@bibr7-2329048X20939003]^ inclusion criteria. Further, we avoided exclusion criteria that could be construed as arbitrary. For example, when considering inborn errors of metabolism, lysosomal sialic acid storage disorder (Salla disease) met inclusion but the lysosomal disorder Niemann-Pick C did not.^[@bibr7-2329048X20939003]^

This finding of a large number of genes that can cause a white matter disorder (leukodystrophy or leukoencephalopathy) highlights that early use of an NGS approach such as whole exome sequencing or whole genome sequencing should be considered as a first-line diagnostic approach. With so many different genes that can cause similar T2 signal changes, NGS can provide lower costs and faster time to diagnosis.^[@bibr23-2329048X20939003]^ For the clinician, this information about the many different genes that can cause GWMD further emphasize the need for early use of NGS in diagnosis.

An important and unresolved question is why this diversity of different genes all cause white matter pathology. In the undertaking of this project, we hypothesized that shared biological mechanisms and pathophysiology would be revealed. We did observe common themes, including overrepresentation of genes involved in metabolism and in mitochondrial function. This suggests, and is concordant with commonly accepted understanding, that the white matter is particularly sensitive to disturbances in metabolism and in energy homeostasis. It is possible that therapies directed toward these downstream targets (metabolic and energy homeostasis) could provide broad benefits for many different GWMD. Another interesting issue is the phenotypic variability, including age of onset and disease severity. This phenotypic diversity is seen even within the same disease, such as X-linked adrenoleukodystrophy or metachromatic leukodystrophy. Thus, while it is not currently possible to generalize about phenotypic presentation or age of onset, perhaps there are patterns of severity that could be experimentally explored. For example, whether diseases with more profound disturbances of energy homeostasis cause an earlier and more severe presentation.

Conclusions {#section4-2329048X20939003}
===========

We found 399 genes that are associated with white matter changes on T2 MR image sequences. This is approximately 10-fold higher than has been standardly considered as the number of genes responsible for leukodystrophies. There are not consistent biological differences between this revised list and previous definitions of leukodystrophy genes. This expanded understanding of the genetics of GWMDs including leukodystrophies and leukoencephalopathies can be useful in analysis and interpretation of NGS results for diagnosis and in understanding the pathophysiology of GWMDs.
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